LI-COR Reports on Toxicity Study of its IRDye 800CW Carboxylate at Global Imaging Summit in Berlin
October 22, 2009 Lincoln, NE/Berlin, Germany: LI-COR Biosciences presented preclinical data on its investigational IRDye® 800CW carboxylate, which is being developed for potential use in clinical applications. To prepare for clinical use as a near-infrared (NIR) fluorophore, a safety study was conducted on IRDye 800CW carboxylate with Sprague Dawley rats. Michael Olive, LI-COR vice president of science and technology, presented the findings of the study at the Global Imaging Summit in Berlin.
“With the current environment of NIR fluorescence instrument development, IRDye 800CW could impact molecular imaging by providing a functionalized NIR dye enabling a variety of new targeting contrast agents,” reports Olive. “Based on hematologic and clinical chemistry evaluations, and histopathologic evaluation of tissues from animals in this study, single administration of IRDye 800CW carboxylate intravenously at dose levels of 1, 5 and 20 mg/kg or 20 mg/kg intradermally followed by up to 14 days of observation produced no pathological evidence of toxicity.”
LI-COR is preparing to submit a Drug Master File on IRDye 800CW to the U.S. Food and Drug Administration. LI-COR anticipates having dye made in compliance with cGMP and available for clinical studies in early 2010.
Optical imaging using near-infrared fluorophores has the potential for use in endoscopy, intraoperative surgical guidance, and imaging the lymphovascular system.
LI-COR Biosciences is a leading provider of near-infrared reagent and detection systems. LI-COR provides complete research solutions for proteomic, genomic and small animal imaging research areas. LI-COR IRDye infrared dyes, optical agents and reagents are well established in the research and pre-clinical markets especially for use in quantitative western blot analysis and in vivo imaging in small animals.
About LI-COR Biosciences: LI-COR Biosciences is a leader in the design and manufacture of instrument systems for biotechnology, plant biology and environmental research. LI-COR is a pioneer in the development of infrared fluorescence labeling and detection systems for such areas as drug discovery and DNA sequencing for genomic research. The Odyssey® and Aerius® systems offer unique infrared imaging solutions for protein analysis of Westerns, micro plate-based assays, and in vivo imaging.
Founded in 1971, the privately held company is based in Lincoln, Nebraska, with subsidiaries in Germany and the United Kingdom. LI-COR systems are used in more than 100 countries and are supported by a global network of distributors. Further information can be obtained at www.licor.com.
